CDC’s Latest Flu Vaccine Effectiveness Estimates: What This Season’s Data Means for You

By Brian Bateman | Public Health Reporting

As of March 2026, the CDC has released its interim estimates of how well this season’s flu vaccine is working in the United States. The headline: this year’s vaccine is providing moderate protection against flu illness serious enough to require medical care.

That may not sound dramatic, but in public health terms, moderate protection can still prevent thousands of doctor visits, hospitalizations, and deaths—especially among older adults, young children, pregnant people, and those with chronic health conditions.

Here’s what the latest data show, how the CDC calculates these numbers, and what they mean for you and your family.

What the CDC’s 2025–2026 Estimates Show

The CDC’s interim findings were published in the Morbidity and Mortality Weekly Report (MMWR), the agency’s primary scientific bulletin. These early-season estimates measure how well the 2025–2026 influenza vaccine reduced the risk of medically attended, laboratory-confirmed flu among people who sought outpatient care.

According to the CDC’s analysis:

Overall vaccine effectiveness (VE) against outpatient flu illness is in the moderate range.
Protection varies by age group, with differences between children, adults under 65, and adults 65 and older.
Effectiveness also varies by virus subtype, including influenza A(H1N1), A(H3N2), and influenza B, depending on which strains are circulating.

As in many recent seasons, effectiveness tends to be somewhat lower in adults 65 and older compared with younger adults and children. That reflects how aging affects the immune system—not a flaw unique to this year’s vaccine.

The CDC also notes that these are interim (mid-season) estimates. As more data are collected, the final numbers may shift.

What Does “Vaccine Effectiveness” Actually Mean?

When you hear that a flu vaccine is, for example, 40–60% effective, that does not mean 40–60% of people are fully protected and the rest get no benefit.

Instead, vaccine effectiveness measures risk reduction. A VE of 50% means vaccinated people had about half the risk of getting flu serious enough to require medical care compared with unvaccinated people.

That still leaves some vaccinated people who may get sick. But it significantly reduces the overall chance of illness across a population.

The CDC calculates VE using what’s called a test-negative design, explained on its influenza vaccine effectiveness page. In simple terms:

Researchers enroll people who seek care for respiratory symptoms.
Everyone is tested for flu.
They compare vaccination rates between those who test positive and those who test negative.

If vaccinated people are less likely to test positive, the vaccine is considered protective.

This design helps reduce bias because all participants were sick enough to seek care—so researchers are comparing similar groups.

Outpatient Illness vs. Severe Disease

The interim MMWR report focuses on protection against outpatient illness—cases that led someone to visit a clinic, urgent care, or emergency department but did not necessarily require hospitalization.

Importantly, flu vaccination often provides stronger protection against hospitalization and death than against milder illness. Even in seasons with moderate effectiveness, vaccines have consistently reduced severe outcomes, particularly among high-risk groups.

Hospitalization-specific effectiveness data often come later in the season, once enough severe cases have been analyzed.

What the Current Flu Season Looks Like

According to the CDC’s current flu season overview, influenza viruses continue to circulate widely across the United States. Activity has varied by region, and both influenza A and B viruses have been detected this season.

The mix of strains matters. Some subtypes—such as A(H3N2)—have historically been associated with more severe seasons and lower vaccine effectiveness in older adults. The degree of match between the vaccine strains and circulating viruses also affects performance.

Because flu viruses change constantly, vaccine composition is updated each year based on global surveillance and recommendations.

What Interim Estimates Can’t Tell Us Yet

Mid-season data are useful, but they have limitations:

Estimates may change. More cases later in the season can shift the numbers.
Sample sizes are smaller. Early data may not fully represent all regions or age groups.
Subtype circulation can change. If a different strain becomes dominant later, effectiveness could differ.
Healthcare-seeking behavior varies. Who chooses to seek care can influence estimates.

For these reasons, CDC describes these findings as interim and cautions against treating them as final.

Why Vaccination Still Matters—Even in a Moderate Year

Some people interpret moderate effectiveness as meaning “the vaccine didn’t work.” That’s not accurate.

Even partial protection can:

Reduce your chance of needing medical care
Lower the risk of hospitalization
Shorten illness duration
Reduce strain on hospitals and clinics

Vaccination is especially important for:

Adults 65 and older
Children under 5, especially under 2
Pregnant people
People with asthma, diabetes, heart disease, kidney disease, or obesity
Residents of nursing homes or long-term care facilities

These groups face higher risks of complications such as pneumonia, worsening chronic conditions, and hospitalization.

How Antivirals Fit In

Vaccination and treatment work together. If you develop flu symptoms—such as high fever, body aches, cough, sore throat, or fatigue—antiviral medications can reduce complications if started early.

CDC recommends prompt antiviral treatment for:

People at higher risk of severe illness
Anyone with severe, progressive, or complicated symptoms
Hospitalized patients

Medications such as oseltamivir (Tamiflu) and baloxavir work best when started within 48 hours of symptom onset, though they may still help high-risk patients later.

If you experience shortness of breath, chest pain, confusion, dehydration, or worsening symptoms, seek medical care promptly.

It’s Not Too Late

As long as flu viruses are circulating, vaccination can still provide benefit. It takes about two weeks after vaccination for antibodies to develop.

For families deciding now, the key takeaway is this: even in a season with moderate effectiveness, the flu vaccine meaningfully lowers the risk of illness serious enough to require medical care—and likely reduces severe outcomes even more.

Bottom Line for U.S. Families

The CDC’s interim 2025–2026 estimates show this year’s flu vaccine is providing measurable protection, though not perfect protection. That’s typical for influenza.

Vaccination remains the most effective preventive tool we have. Combined with early testing and timely antiviral treatment, it reduces the personal and community impact of flu season.

If you or a family member is in a higher-risk group, vaccination and early medical attention for symptoms are especially important. And if you haven’t gotten vaccinated yet, there is still time while flu viruses continue to circulate.

In public health, partial protection at scale still saves lives.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.